AstraZeneca expands Bengaluru hub with Rs 166 crore investment; to create 400 jobs
BENGALURU: Biopharmaceutical company AstraZeneca on Thursday announced the expansion of its global hub in Bengaluru with Rs 166 crore investment. The new facility will house about 1,300 employees and generate 400 new jobs.
This is AstraZeneca's second major investment in India within a year, following the expansion of its Global Innovation and Technology Centre (GITC) in Chennai. The combined workforce now at AstraZeneca India Private Limited (AZIPL) will reach close to 4,000 employees.
The company said the new facility will serve as a dynamic hub dedicated to advancing AstraZeneca's critical priorities including advanced clinical research supporting AstraZeneca's global therapeutic areas; development of AI-powered; healthcare solutions and digital health technologies.
Apart from these, the new facility will help centralise data analytics to enhance clinical trial efficiency and patient outcomes.
"Our Global Hub in Bengaluru is a strategic investment that will play a vital role in advancing AstraZeneca's bold ambition to deliver 20 new medicines by 2030 — by strengthening automated, scalable, data-driven, and patient-centric solutions. This step reflects our commitment to tapping into the world-class talent and ecosystem available in Karnataka to power the next generation of scientific innovation," said Jackie Crockford, Vice President, Global Business Services, AstraZeneca.
"This hub enhances our R&D capabilities by connecting us with India's exceptional scientific and technological expertise. The expansion will accelerate the development of innovative medicines and help us deliver across R&D, ultimately benefiting patients around the world," said Magnus Nord, Vice President, Global Patient Safety BioPharma, AstraZeneca.
The global hub in Bengaluru is dedicated to Research & Development (R&D), Global Business Services (GBS), IT & Digital Health capabilities, playing a key role in advancing scientific discovery and innovation within the enterprise.
The company also said that the GITC in Chennai serves as a strategic hub for IT, GBS, Global supply chain & strategy, supporting core business operations with high-impact, technology-driven solutions.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
United News of India
2 minutes ago
- United News of India
CEL playing a leading role in data centers and green energy: CM Yogi
Ghaziabad, Jun 26(UNI) Uttar Pradesh Chief Minister Yogi Adityanath on Thursday described Central Electronics Limited (CEL)'s journey as a symbol of India's industrial revival and self-reliance. He said that CEL is a key part of Prime Minister Modi's vision for a developed India by 2047, and that through organizations like these, new India is moving forward with strength, technology, and confidence. CM Yogi and Union Minister of State (Independent Charge) for Science & Technology, Dr. Jitendra Singh, laid the foundation stone for the CEL-ESDS Green Data Centre in Sahibabad, Ghaziabad on Thursday. During the event, the CM expressed happiness about the new greenfield data centre being developed by CEL. He said, ' It is a strong step toward achieving PM Modi's goal of net-zero emissions by 2070.' He also mentioned that Uttar Pradesh will generate 20,000 megawatts of renewable energy by 2027, with CEL playing a key role in this mission. At the Golden Jubilee celebration of Central Electronics Limited (CEL) in Ghaziabad and the foundation stone-laying ceremony of its new data center, CM Yogi took part in the Puja and also visited the exhibition, where he was given information about the data center and its operations. He also planted a sapling as part of the 'Ek Ped Maa Ke Naam' campaign. During the event, CEL also handed over a cheque worth Rs 21 crore to the Government of India, and an MoU was exchanged between CEL and Multi Infra for a 200 MW solar module project. Speaking at the event, the CM described CEL's 50-year journey as an inspiring success story, saying that the company has now entered the "Amrit Kaal" and is playing a key role in fulfilling PM Modi's vision of a developed India. He recalled that there was a time when CEL faced uncertain days and was even put on the list for disinvestment. 'However, today CEL has become a profit-making 'Mini Ratna' company and is handing over dividends to the government. This change is an inspiration for Atmanirbhar (Self-Reliant) India,' he added. The CM praised CEL for its innovations in sectors like railways, defence, renewable energy, and education. He said that CEL's technology and creativity are making the nation stronger. Highlighting its contributions, the Chief Minister noted that CEL plays a key role in areas such as smart classrooms, signaling systems, renewable energy modules, and defence equipment. He also mentioned that CEL made India's first solar photovoltaic module in 1974 and is now setting up the country's first greenfield data center. Talking about the Defence Manufacturing Corridor, he said that equipment for BrahMos missiles is also being produced with the help of organizations like CEL. Referring to Operation Sindoor, CM Yogi said that BrahMos and Akash missiles were recently used against Pakistan. 'We can say that the capacity of both these missiles have been 'tested' in Pakistan and 'trusted' worldwide,' he remarked. The Chief Minister also linked CEL's progress to the changing image of Uttar Pradesh. He said that in the past eight years, the state's economy has grown 2.5 times, lifting 6 crore people out of poverty. Investors are now eager to invest in Uttar Pradesh, which was earlier known as a backward state. 'Today, Uttar Pradesh is becoming the growth engine of the country,' he added. Out of Rs 50 lakh crore worth of investment proposals, Rs 15 lakh crore of investments have already started production after the groundbreaking ceremonies. Speaking about CEL's journey, CM Yogi said, 'Your childhood was good, then you faced some challenges in your youth, but now you have entered your Amrit Kaal.' This is a period of the next 25 years dedicated to making India self-reliant and developed. He added that Prime Minister Modi has often stressed the need to connect educational institutions with industry, and Uttar Pradesh has excellent institutes like IITs, IIMs, universities, and central laboratories to help achieve this goal. Union Minister of State (Independent Charge) for Science and Technology, Dr. Jitendra Singh, said that CEL has its own legacy. The company invented the first solar cell back in 1970, and now, 50 years later, it is about to set up a green data center. He praised Chief Minister Yogi Adityanath, saying, 'Your name is already part of history for the construction of the Ram Temple in Ayodhya, and I'm happy that two institutions under my ministry also contributed to it.' He also announced that the country's first quantum unit will soon be established at IIT Noida. In addition, a biotechnology park will be set up near Lucknow, and a two- or three-day startup conclave is planned for August. UNI MBD RKM
The Print
4 minutes ago
- The Print
In battle for Indian anti-obesity market, Eli Lilly's pre-filled pen on one side, Novo Nordisk's on other
The Central Drugs Standard Control Organisation (CDSCO) has granted marketing authorisation for Mounjaro in the KwikPen presentation, Eli Lilly said in a statement Thursday, adding that the approval marks an important step in advancing care for people living with type 2 diabetes and obesity in India. Mounjaro by US-based Eli Lilly & Company, which has tirzepatide as its active pharmaceutical ingredient (API), was launched in India on 20 March this year in vial format, which meant it was more cumbersome to administer. New Delhi: Eli Lilly India, makers of the obesity drug Mounjaro, said Thursday that they have received approvals from the Indian regulator for their pre-filled pen, a day after competitor Novo Nordisk's global mega-selling drug for obesity, Wegovy, hit the Indian markets. The pens offer a convenient way for patients to take their medication. First developed as a treatment for type 2 diabetes in lower doses, both Mounjaro and Wegovy are weekly injections intended to dramatically reduce weight in obese patients. They have emerged as global sensations in the pharmaceutical market world over, with their sales reaching multi-billion-dollar figures. These drugs have also been fighting to dominate the obesity management space in many developed countries. They are now aiming to capture a share of the market in India, where obesity is growing rapidly, driven by changing dietary and lifestyle patterns. India's anti-obesity drug market is currently valued at Rs 3,000-3,500 crore, and is projected to grow nearly eightfold to Rs 25,000 crore by 2030, according to market estimates. A 2023 survey by the Indian Council of Medical Research (ICMR) and Madras Diabetes Research Foundation (MDRF) had shown that 25.4 crore Indians, or 28.6 percent, of the population had generalised obesity. Obesity, now recognised as a chronic, relapsing disease, is a major risk factor for diabetes and is linked to over 200 health complications, including hypertension, dyslipidemia or high blood cholesterol, coronary heart disease, and obstructive sleep apnea. Also Read: Fat-busting drug Mounjaro launched in India. Here's how much it will cost Promise of simplified treatment KwikPen, or Mounjaro, is a multi-dose, prescription-based, single-patient-use pre-filled pen designed for once-weekly administration, the company said. It also added that the full range of doses for Mounjaro—2.5 mg to 15 mg—will be available in India soon, supporting personalised treatment as recommended by treating physicians. Earlier, the vial format of the drug was launched in only two dosage strengths—2.5 mg and 5 mg—in the country. The latest announcement came after Wegovy, which has semaglutide as its API, got a strategic launch in India as an innovative, easy-to-use pre-filled pen called FlexTouch devices. It was aimed at stealing the thunder Mounjaro had by reaching Indian patients first. A less potent version of semaglutide, in the form of an oral pill-under the brand name of Rybelsus, has been available in India since 2022 for the treatment of diabetes. The Wegovy pre-filled pen has been launched in five dosing strengths: 0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg. While the monthly cost of the first three dosages is Rs 17,345, the higher doses will cost Rs 24,280 and Rs 26,050, respectively. Mounjaro, in the vial format, was launched at a cost of Rs 14,000 (for 2.5 mg) and Rs 17,500. Eli Lilly, however, has yet to decide the price of the Mounjaro KwikPen for all five dosages. Meanwhile, experts ThePrint spoke to said pre-filled pens will simplify treatment, making these powerful anti-obesity and diabetes medications more convenient for patients. 'With simplified administration, adherence improves, helping more individuals achieve better weight and metabolic health outcomes,' explained Mumbai-based diabetologist Dr Rajiv Kovil. Senior diabetologist and researcher Dr V. Mohan also said this could make a profound impact on the lives of lakhs of people in India. Mounjaro vs Wegovy—which is more effective Both tirzepatide and semaglutide, the prescription-only drugs, mimic the effects of natural gut hormones that work by lowering caloric intake, primarily by influencing appetite control mechanisms. Tirzepatide is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, while semaglutide functions as a mono GLP-1 receptor agonist. Both GIP and GLP-1 are natural incretin hormones, that stimulate a decrease in blood glucose levels, found in brain regions that regulate appetite. In May this year, Lilly said in a statement that a head-to-head clinical trial comparing tirzepatide and semaglutide in their maximum tolerable doses showed the former to be significantly more effective than the latter in reducing both weight and waist circumference after 72 weeks of treatment. According to the US-based pharma giant, participants administered tirzepatide saw an average weight reduction of 20.2 percent, while those on semaglutide experienced a 13.7 percent loss—indicating a 47 percent greater relative weight loss for the former, based on the treatment regimen estimated at 72 weeks. But one advantage that semaglutide has in the higher dose strength is its ability to also treat several other metabolic conditions, such as cardiovascular diseases and kidney disorders. While Mounjaro is better than Wegovy in percentage of weight loss, there is stronger evidence in the case of Wegovy for reducing cardiovascular conditions in obese people without diabetes and also for treating kidney and diabetes, experts said. During the launch of Wegovy on 24 June, Novo Nordisk underlined that the drug is the only medication approved in India for treating major adverse cardiovascular events (MACE), along with obesity. Diabetologist Kovil said, 'If there is an obese patient who does not have other major underlying issues yet, I will be more inclined towards prescribing Mounjaro.' He added that, in patients with comorbidities such as diabetes, liver or kidney disorder or cardiovascular condition, Wegovy could be a better choice as it reduces mortality and improves longevity. In response to queries by ThePrint, Eli Lilly said that Mounjaro offers a novel approach to metabolic health management, giving treating physicians an innovative option for treating both diabetes and obesity. 'Ultimately, it is up to physicians to determine the most appropriate treatment based on individual patient needs and clinical judgment,' said the drugmaker. According to Dr Ambrish Mithal, chairman and head, endocrinology and diabetes with Max Healthcare, anti-obesity drugs can be indicated for people with a BMI (Body Mass Index) of 30 and above in the absence of other comorbidities. However, in people with other pre-existing conditions, either of the drugs can be initiated at a BMI of 27 and above, in conjunction with diet, lifestyle changes and under expert supervision, he said. Experts also warn about the possible side effects of GLP-1 agonist drugs amid concerns around misuse of these drugs in India, given the regulatory loopholes which allow patients to access most prescription drugs over the counter. Large clinical trials and post-marketing evidence following use of these medicines have shown that while nausea, bloating, vomiting and diarrhoea are comparatively mild side effects of these medications. In rare cases, they can also cause stomach paralysis, a disorder that affects the normal movement of the stomach muscles. In a response to queries by ThePrint, Eli Lilly emphasised that Mounjaro is a prescription-only drug and should be taken strictly under a doctor's supervision. 'Tirzepatide is not approved for, and should not be used for, cosmetic weight loss or by individuals under 18. Lilly neither promotes nor encourages the unapproved use of tirzepatide by anyone,' the company said. (Edited by Sanya Mathur) Also Read: Mounjaro will shrink India's appetite for packaged food, gyms, weight loss supplements
New Indian Express
7 minutes ago
- New Indian Express
June sees 8 large IPOs, 30 SME issues raising over Rs 19,000 crore
MUMBAI: The second half of June has seen a raining of IPOs as the primary market activity sharply rebounded after a drought in the previous two months. The current month has seen eight large IPOs, led by the largest NBFC issue in HDB Financial's Rs 12,500 crore issue, and as many as 30 SME issues hitting the street raising over Rs 19,000 crore. Eight mainboard IPOs have collectively raised around Rs 17,700 crore (only HDB is ongoing and closes Friday and all other issues have already been closed), the highest monthly fundraising via IPOs in the past six months. In the SME segment, the month saw as many as 30 IPOs, raising around Rs 1,330 crore, a nine-month high. The SME space activity is interesting as the Sebi has done a lot of regulatory tightening after many incidents of fund miss-use and price-rigging at the pre-issue level by promoters and i-bankers. Analysts attribute the surge in IPOs to the regulatory timelines imposed by Sebi, prompting companies to expedite listings to avoid re-filing amid market uncertainty.
